[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"zoster\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:zoster":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100643497","reduced-vaccine-response-to-hzsu-in-sle-100643497",false,"NCT07636044","Reduced Vaccine Response to HZ\u002Fsu in SLE","Reduced Cell-mediated Immune Response to 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Males or females ≥ 50 years of age at time of consent\n* ≥ 4 of the 1997 ACR13 or the 2012 SLICC\u002FACR criteria for SLE (14, 15)\n* Clinically stable SLE\n* Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks\n* Corticosteroid use: ≥ 5mg\u002Fday of prednisolone equivalent\n* Antimalarials (≤ 400 mg\u002Fday)\n* Azathioprine (≤ 3 mg\u002Fkg\u002Fday)\n* Mycophenolate mofetil (≤ 3 mg\u002Fday)\n* Tacrolimus (≤ 5mg\u002Fday)\n* Methotrexate (≤ 20mg\u002Fweek)\n* Cyclosphosphamide (≤ 1mg\u002FBSA\u002Fmonth)\n* Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine\n* Must understand and voluntarily sign an informed consent form including writing consent for data protection\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Acute infection with temperature \\>38C at the time of vaccination\n* Previous anaphylactic response to vaccine components or to egg\n* History of Guillain-Barre syndrome or demyelinating syndromes\n* Any condition including laboratory abnormality which places the subject at unacceptable risk\n* Subjects who decline to participate",true,"ALL","50 Years",{"count":20,"type":21},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ\u002Fsu, \"Shingrix\") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.",[25,26,27],"Vaccine Reaction","Zoster","Systemic Lupus Erythematosus","RECRUITING","2026-06-04",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":32},"2024-10-01",{"date":36,"type":21},"2030-10-01",{"name":38,"class":39},"Seoul National University Hospital","OTHER"]